{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T09:20:13Z","timestamp":1777972813570,"version":"3.51.4"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T00:00:00Z","timestamp":1763856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T00:00:00Z","timestamp":1763856000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s40123-025-01275-z","type":"journal-article","created":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T06:01:53Z","timestamp":1763877713000},"page":"457-465","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Use of Tacrolimus for the Treatment of Pediatric Noninfectious Uveitis"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-4755-0639","authenticated-orcid":false,"given":"Ingrid","family":"Pan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan G.","family":"Palestine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca G.","family":"Edwards Mayhew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer L.","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,23]]},"reference":[{"key":"1275_CR1","first-page":"279","volume-title":"Textbook of pediatric rheumatology","author":"ES Sen","year":"2021","unstructured":"Sen ES, Ramanan AV, Rosenbaum JT. Uveitis in juvenile idiopathic arthritis. In: Petty RE, Laxer RM, Lindsley CB, editors. Textbook of pediatric rheumatology. Philadelphia: Elsevier; 2021. p. 279\u201394."},{"issue":"17","key":"1275_CR2","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa1614160","volume":"376","author":"AV Ramanan","year":"2017","unstructured":"Ramanan AV, Dick AD, Jones AP, McKay A, Williamson PR, Compeyrot-Lacassagne S, et\u00a0al. Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis. N Engl J Med. 2017;376(17):1637\u201346.","journal-title":"N Engl J Med"},{"issue":"8","key":"1275_CR3","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1136\/annrheumdis-2018-213131","volume":"77","author":"T Constantin","year":"2018","unstructured":"Constantin T, Foeldvari I, Anton J, de Boer J, Czitrom-Guillaume S, Edelsten C, et\u00a0al. Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative. Ann Rheum Dis. 2018;77(8):1107\u201317.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1275_CR4","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1001\/archopht.123.5.634","volume":"123","author":"CC Murphy","year":"2005","unstructured":"Murphy CC, Greiner K, Plskova J, Duncan L, Frost NA, Forrester JV, et\u00a0al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Arch Ophthalmol. 2005;123(5):634\u201341.","journal-title":"Arch Ophthalmol"},{"issue":"6","key":"1275_CR5","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/j.ophtha.2011.12.030","volume":"119","author":"RW Lee","year":"2012","unstructured":"Lee RW, Greenwood R, Taylor H, Amer R, Biester S, Heissigerova J, et\u00a0al. A randomized trial of tacrolimus versus tacrolimus and prednisone for the maintenance of disease remission in noninfectious uveitis. Ophthalmology. 2012;119(6):1223\u201330.","journal-title":"Ophthalmology"},{"issue":"7","key":"1275_CR6","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1136\/bjophthalmol-2017-310436","volume":"102","author":"F Islam","year":"2018","unstructured":"Islam F, Westcott M, Rees A, Robson AG, Kapoor B, Holder G, et\u00a0al. Safety profile and efficacy of tacrolimus in the treatment of birdshot retinochoroiditis: a retrospective case series review. Br J Ophthalmol. 2018;102(7):983\u201390.","journal-title":"Br J Ophthalmol"},{"issue":"7\u20138","key":"1275_CR7","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1080\/09273948.2021.1930063","volume":"30","author":"J Luis","year":"2022","unstructured":"Luis J, Alsaedi A, Phatak S, Kapoor B, Rees A, Westcott M. Efficacy of tacrolimus in uveitis, and the usefulness of serum tacrolimus levels in predicting disease control. Results from a single large center. Ocul Immunol Inflamm. 2022;30(7\u20138):1654\u20138.","journal-title":"Ocul Immunol Inflamm"},{"issue":"9","key":"1275_CR8","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1097\/IAE.0000000000003836","volume":"43","author":"DA Jabs","year":"2023","unstructured":"Jabs DA, Thorne JE, Wilkins CS, Habbu KA, Berkenstock MK, Burkholder BM, et\u00a0al. Tacrolimus for immunosuppression in patients with noninfectious intermediate, posterior, or panuveitides. Retina. 2023;43(9):1480\u20136.","journal-title":"Retina"},{"issue":"3","key":"1275_CR9","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","volume":"140","author":"DA Jabs","year":"2005","unstructured":"Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140(3):509\u201316.","journal-title":"Am J Ophthalmol"},{"key":"1275_CR10","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.ajo.2021.03.045","volume":"228","author":"Standardization of Uveitis Nomenclature (SUN) Working Group","year":"2021","unstructured":"Standardization of Uveitis Nomenclature (SUN) Working Group. Classification criteria for pars planitis. Am J Ophthalmol. 2021;228:268\u201374.","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"1275_CR11","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3109\/09273948.2013.767353","volume":"21","author":"SS Salek","year":"2013","unstructured":"Salek SS, Leder HA, Butler NJ, Gan TJ, Dunn JP, Thorne JE. Periocular triamcinolone acetonide injections for control of intraocular inflammation associated with uveitis. Ocul Immunol Inflamm. 2013;21(4):257\u201363.","journal-title":"Ocul Immunol Inflamm"},{"issue":"2","key":"1275_CR12","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s40123-022-00480-4","volume":"11","author":"JL Jung","year":"2022","unstructured":"Jung JL, Harasawa M, Patnaik JL, Palestine AG. Subtenon triamcinolone acetonide injection with topical anesthesia in pediatric non-infectious uveitis. Ophthalmol Ther. 2022;11(2):811\u201320.","journal-title":"Ophthalmol Ther"},{"issue":"2","key":"1275_CR13","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.ajo.2012.08.010","volume":"155","author":"SE Yanni","year":"2013","unstructured":"Yanni SE, Wang J, Cheng CS, Locke KI, Wen Y, Birch DG, et\u00a0al. Normative reference ranges for the retinal nerve fiber layer, macula, and retinal layer thicknesses in children. Am J Ophthalmol. 2013;155(2):354-360.e1.","journal-title":"Am J Ophthalmol"},{"key":"1275_CR14","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ajo.2022.06.024","volume":"244","author":"V Miraldi Utz","year":"2022","unstructured":"Miraldi Utz V, Angeles-Han ST, Mwase N, Cassedy A, Hennard T, Lovell DJ, et\u00a0al. Alternative biologic therapy in children failing conventional TNF\u03b1 inhibitors for refractory, non-infectious, chronic anterior uveitis. Am J Ophthalmol. 2022;244:183\u201391.","journal-title":"Am J Ophthalmol"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01275-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-025-01275-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01275-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T08:32:44Z","timestamp":1770453164000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-025-01275-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,23]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1275"],"URL":"https:\/\/doi.org\/10.1007\/s40123-025-01275-z","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,23]]},"assertion":[{"value":"12 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ingrid Pan has served as consultant for Pharming Pharmaceuticals and Sobi\u2014Swedish Orphan Biovitrium AB (Sobi) and currently serves as a consultant for Wolters Kluwer Clinical Drug Information, Inc\u2014Lexicomp\n                      \u00ae\n                      . Alan G. Palestine serves as a consultant for Tarsier Pharma. Clara Lin has served as a consultant for Pharming Pharmaceuticals. Rebecca G. Edwards Mayhew and Jennifer L. Jung declare that they have no competing interests. Alan G. Palestine is an Editorial Board member of\n                      Ophthalmology and Therapy\n                      . Alan G. Palestine was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was approved by the Colorado Multiple Institutional Review Board (21-3192) and followed the tenets of the Declaration of Helsinki and the Health Insurance Portability and Accountability Act of 1996 (HIPAA). The requirement of informed consent was waived, as this study was retrospective. Patients were not involved in the study trial design or dissemination of results.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}